AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

AC Immune S.A.NASDAQ: ACIU

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -CHF 13K, compared with CHF 341K a year earlier. Trailing-twelve-month other income / expenses was -CHF 1.47M.

Context

  • Other income / expenses amounted to 44.3% of revenue in FY2025, up 39.0 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -CHF 13K or moves back toward the trailing-twelve-month quarterly average of -CHF 368.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 13K-139.4% QoQ
Last fiscal yearDec 2025
-CHF 1.58M-208.1% YoY
LTMMar 2026
-CHF 1.47M-268.3% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-103.8%——
1 year-208.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

CHF · from the income statement

Latest · FY2025
(1.58M) CHF
Year-over-year change
-208.1%

Other Income / Expenses vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -268.3% is the 7th highest of 10, against a peer median of -79.4%.
  • Other income / expenses amounts to 39.8% of revenue for ACIU, versus a peer median of 155.2%.
ACIU Competitors
Other Income / Expenses for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$8.58M USD-44.7%+38.6%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$8.41M USD+109.1%——
AMRNAmarin Corporation plcLTM Mar 2026$2.64M USD-79.4%—1.2%
MREOMereo BioPharma Group plcLTM Mar 2026$1.86M USD+124.8%—372.3%
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-70.6%+29.4%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 1.47M CHF-268.3%—39.8%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$10.57M USD-331.3%——
CLLSCellectis S.A.LTM Mar 2026-$23.45M USD-215.6%—34.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M USD-309.6%—175948.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026-$129.21M USD-2023.6%+28.2%—
Peer median (excluding ACIU) —-79.4%+28.8%155.2%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.